Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn’s Disease Who Failed Biologic Therapies: A National Cohort Study
Claire Liefferinckx, Séverine Vermeire(KU Leuven), Catherine Van Kemseke(Centre Hospitalier Universitaire de Liège), Martine De Vos(Erasmus MC), Peter Bossuyt(Imelda Hospital), Dirk Staessen, Denis Franchimont(McGill University Health Centre), Bram Verstockt(Universitair Ziekenhuis Leuven), Evelien Humblet, Jean‐François Rahier(CHU Dinant Godinne UCL Namur), Édouard Louis(Centre Hospitalier Universitaire de Liège), Joris Dutré(Goethe University Frankfurt), Ann Gils(KU Leuven), Philippe Van Hootegem(AZ Sint-Lucas), Filip Baert(AZ Delta), Maja Noman(KU Leuven), Wouter Van Moerkercke, Elisabeth Macken(Province of Antwerp), Harald Peeters(Ghent University Hospital)
Cited by 121
Related Papers
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci
|Nature Genetics|2010|2.6k
ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications
|Journal of Crohn s and Colitis|2018|1.8k